Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jan;96(1):365-408.
doi: 10.1152/physrev.00014.2015.

Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects

Sylvia Christakos  1 , Puneet Dhawan  1 , Annemieke Verstuyf  1 , Lieve Verlinden  1 , Geert Carmeliet  1
Affiliations
Review

Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects

Sylvia Christakos et al. Physiol Rev. 2016 Jan.

Abstract

1,25-Dihydroxvitamin D3 [1,25(OH)2D3] is the hormonally active form of vitamin D. The genomic mechanism of 1,25(OH)2D3 action involves the direct binding of the 1,25(OH)2D3 activated vitamin D receptor/retinoic X receptor (VDR/RXR) heterodimeric complex to specific DNA sequences. Numerous VDR co-regulatory proteins have been identified, and genome-wide studies have shown that the actions of 1,25(OH)2D3 involve regulation of gene activity at a range of locations many kilobases from the transcription start site. The structure of the liganded VDR/RXR complex was recently characterized using cryoelectron microscopy, X-ray scattering, and hydrogen deuterium exchange. These recent technological advances will result in a more complete understanding of VDR coactivator interactions, thus facilitating cell and gene specific clinical applications. Although the identification of mechanisms mediating VDR-regulated transcription has been one focus of recent research in the field, other topics of fundamental importance include the identification and functional significance of proteins involved in the metabolism of vitamin D. CYP2R1 has been identified as the most important 25-hydroxylase, and a critical role for CYP24A1 in humans was noted in studies showing that inactivating mutations in CYP24A1 are a probable cause of idiopathic infantile hypercalcemia. In addition, studies using knockout and transgenic mice have provided new insight on the physiological role of vitamin D in classical target tissues as well as evidence of extraskeletal effects of 1,25(OH)2D3 including inhibition of cancer progression, effects on the cardiovascular system, and immunomodulatory effects in certain autoimmune diseases. Some of the mechanistic findings in mouse models have also been observed in humans. The identification of similar pathways in humans could lead to the development of new therapies to prevent and treat disease.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
The metabolic pathway for vitamin D. CYP2R1 has been identified as a key vitamin D 25-hydroxylase. PTH, FGF23/klotho, and 1,25(OH)2D3 play key roles in the regulation of optimal levels of 1,25(OH)2D3. Only products of 1,25(OH)2D3 are represented for the C23 lactone pathway. See text for 25(OH)D products of the C23 lactone pathway.
Figure 2.
Figure 2.
Structure of the full human RXR/VDR nuclear receptor heterodimeric complex with its target DNA. The structure of the RXR/VDR complex was determined by single particle cryo-EM and 3D reconstruction. Representation of the cryo-EM map with the fitted crystal structure of the individual RXR and VDR LBDs and DBDs resulting in a molecular model of the full RXR/VDR/DNA complex (top view of the complex). It has been suggested that the carboxy-terminal extension (CTE) of the DBD of VDR extending into the hinge region has a critical role for VDR transcriptional activity. The LBD interface contact comprising helix 4, loop 8/9 of VDR, and helix H7 of RXR is marked with a star. [Adapted from Orlov et al. (335), with permission from John Wiley and Sons.]
Figure 3.
Figure 3.
Effects of 1,25(OH)2D3 in the intestine. An important function of 1,25(OH)2D3 is the stimulation of transcellular intestinal calcium transport by increasing the expression of the apical membrane calcium channel TRPV6 and calcium binding protein calbindin-D9k. The extrusion of calcium is across the basolateral membrane by PMCA1b. This process is especially enhanced when dietary calcium intake is low. Mouse genetic studies however suggest that other calcium transporters (X) are likely involved. When calcium intake is high, the paracellular calcium transport prevails, but studies suggest that this pathway may also be regulated by 1,25(OH)2D3.
Figure 4.
Figure 4.
Transgenic (TG) expression of VDR specifically in ileum, cecum, and colon of VDR null mice prevents the abnormal calcium phenotype of VDR null mice. A: the full-length hVDR cDNA was introduced into the multiple cloning cassette under control of the 9.5-kb CDX2 promoter region (9.5 kb CDX2 from E. Fearon). Mice expressing VDR exclusively in the ileum, cecum, and colon were generated by breeding VDR null mice with TG mice expressing hVDR under the control of 9.5-kb CDX2. B, top panel: expression of hVDR was restricted to ileum, cecum, and colon. Mouse (m) VDR was present in WT but not in TG mice or VDR null (KO) mice. Levels of VDR in the distal intestine in TG mice were equivalent or 1.5 upregulated compared with WT. Bottom panel: Van Kossa staining of histolocial sections of tibia showing that the expression of hVDR in the distal intestine (KO/TG1 and KO/TG2) rescues the bone defects associated with systemic VDR deficiency. Serum PTH and serum calcium are normalized in KO/TG1 and KO/TG2 mice (not shown). [From Dhawan et al. (112).]
Figure 5.
Figure 5.
Renal VDR actions. In the proximal tubule cells, CYP27B1 expression is suppressed by 1,25(OH)2D3 and FGF23. FGF23 also stimulates phosphate excretion by decreasing the expression of the phosphate transporters NPT2a/c in the apical membrane. FGF23 may signal by binding to the few FGFR1-Klotho complexes in the proximal tubules or by inducing a paracrine factor (factor X) in the distal tubules where abundant FGFR1-Klotho complexes are present. Renal calcium reabsorption in the distal tubule is stimulated by 1,25(OH)2D3. 1,25(OH)2D3 increases the expression of calbindin-D9k and calbindin-D28k and to a lesser extent of TRPV5. The extrusion of calcium at the basolateral side is mediated by PMCA1b and NCX1. Two models are proposed on how Klotho and FGF23 regulate TRPV5 expression: 1) secreted Klotho (sKlotho) is considered to hydrolyze sugar residues from the glycan chains on TRPV5 resulting in better entrapment of TRPV5 in the apical membrane; and 2) FGF23 binds to the basolateral FGFR1-Klotho complex, which stimulates intracellular transport of TRPV5 to the plasma membrane.
Figure 6.
Figure 6.
Skeletal effects of 1,25(OH)2D3 signaling. During a negative calcium balance, when VDR action in the intestine is impaired or dietary calcium intake is low, intestinal calcium absorption is decreased. Normal serum calcium levels can however be maintained by increased 1,25(OH)2D3 and PTH levels, which will increase bone resorption and reduce bone matrix mineralization. During a normal or positive calcium balance, normal serum 1,25(OH)2D3 levels promote intestinal calcium absorption. This pathway will deliver sufficient calcium for adequate bone matrix mineralization. VDR signaling in osteoprogenitors increases RANKL expression and stimulates osteoclastogenesis, whereas VDR action in mature osteoblasts has anticatabolic actions, by decreasing RANKL expression, and anabolic effects by stimulating LRP-5 signaling.
Figure 7.
Figure 7.
1,25(OH)2D3-induced signaling pathways involved in the regulation of cell proliferation, apoptosis, and inflammation in cancer. 1,25(OH)2D3 hampers the transition from the G1 to the S phase of the cell cycle either directly, through upregulation of different cyclin-dependent kinase inhibitors, or indirectly through the induction of other growth factors (e.g., TGF-β, EGF). In addition, 1,25(OH)2D3 induces apoptosis through activation of the intrinsic apoptotic pathway or by interference with other signaling pathways such as TNF-α, EGF, β-catenin, and prostaglandins. 1,25(OH)2D3 has also an immunosuppressive activity, as indicated by the repression of NFκB-mediated gene transcription, which results in a suppressed production of inflammatory cytokines, such as IL-1, IL-6, IL-8, and TNF-α.
Figure 8.
Figure 8.
Cooperative effects of dietary vitamin D and IFN-β treatments in attenuation of EAE. On day 0, EAE was induced by immunization with myelin oligodendrocyte glycoprotein (MOG) p35-55 in C57BL/6 mice and scored daily for degree of paralysis. On day 5, the diet was changed to 20 IU vitamin D/g diet or left at 1.5 IU vitamin D/g diet. On day 7, treatment with IFN-β (a first line treatment for multiple sclerosis) was initiated and continued every other day through day 16. The combination of high-dose vitamin D and IFN-β was more effective than high dietary vitamin D alone or IFN-β alone in diminishing paralysis in EAE (R. Axtell, L. Steinman, and S. Christakos, unpublished data).
Figure 9.
Figure 9.
Chemical structure of 1,25(OH)2D3 and possible analog modifications.
Figure 10.
Figure 10.
Overview of clinically approved vitamin D analogs.
See this image and copyright information in PMC

Similar articles

  • Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline.
    Demay MB, Pittas AG, Bikle DD, Diab DL, Kiely ME, Lazaretti-Castro M, Lips P, Mitchell DM, Murad MH, Powers S, Rao SD, Scragg R, Tayek JA, Valent AM, Walsh JME, McCartney CR. Demay MB, et al. J Clin Endocrinol Metab. 2024 Jul 12;109(8):1907-1947. doi: 10.1210/clinem/dgae290. J Clin Endocrinol Metab. 2024. PMID: 38828931
  • Influence of Vitamin D Receptor Signalling and Vitamin D on Colonic Epithelial Cell Fate Decisions in Ulcerative Colitis.
    Kellermann L, Hansen SL, Maciag G, Granau AM, Johansen JV, Teves JM, Bressan RB, Pedersen MT, Soendergaard C, Baattrup AM, Hammerhøj A, Riis LB, Gubatan J, Jensen KB, Nielsen OH. Kellermann L, et al. J Crohns Colitis. 2024 Oct 15;18(10):1672-1689. doi: 10.1093/ecco-jcc/jjae074. J Crohns Colitis. 2024. PMID: 38747639 Free PMC article.
  • RETRACTED: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
    Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Tissot Dupont H, Honoré S, Colson P, Chabrière E, La Scola B, Rolain JM, Brouqui P, Raoult D. Gautret P, et al. Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20. Int J Antimicrob Agents. 2020. Retraction in: Int J Antimicrob Agents. 2025 Jan;65(1):107416. doi: 10.1016/j.ijantimicag.2024.107416 PMID: 32205204 Free PMC article. Retracted. Clinical Trial.
  • Autoimmune Lymphoproliferative Syndrome.
    Bleesing JJH, Nagaraj CB, Zhang K. Bleesing JJH, et al. 2006 Sep 14 [updated 2017 Aug 24]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. 2006 Sep 14 [updated 2017 Aug 24]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. PMID: 20301287 Free Books & Documents. Review.
  • Isolated Methylmalonic Acidemia.
    Manoli I, Sloan JL, Venditti CP. Manoli I, et al. 2005 Aug 16 [updated 2022 Sep 8]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. 2005 Aug 16 [updated 2022 Sep 8]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. PMID: 20301409 Free Books & Documents. Review.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nature Genet 26: 345–348, 2000. - PubMed
    1. Abdul Gafor AH, Saidin R, Loo CY, Mohd R, Zainudin S, Shah SA, Norella KC. Intravenous calcitriol versus paricalcitol in haemodialysis patients with severe secondary hyperparathyroidism. Nephrology 14: 488–492, 2009. - PubMed
    1. Abe E, Miyaura C, Sakagami H, Takeda M, Konno K, Yamazaki T, Yoshiki S, Suda T. Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3. Proc Natl Acad Sci USA 78: 4990–4994, 1981. - PMC - PubMed
    1. Adams JS, Sharma OP, Gacad MA, Singer FR. Metabolism of 25-hydroxyvitamin D3 by cultured pulmonary alveolar macrophages in sarcoidosis. J Clin Invest 72: 1856–1860, 1983. - PMC - PubMed
    1. Adorini L, Penna G, Amuchastegui S, Cossetti C, Aquilano F, Mariani R, Fibbi B, Morelli A, Uskokovic M, Colli E, Maggi M. Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol). J Steroid Biochem Mol Biol 103: 689–693, 2007. - PubMed

Publication types

MeSH terms